Monday, 20 Jan 2020

Biologic/Novel Rx

Datesort ascending Type Title Save
02 Jan 2020 News Best of 2019 - Is Methotrexate Necessary with Tofacitinib?
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb
31 Dec 2019 News Best of 2019 - Ups and Downs with Abatacept
30 Dec 2019 News Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?
26 Dec 2019 News Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots
25 Dec 2019 News Best of 2019 - Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis
23 Dec 2019 News Gilead Submits Filgotinib NDA to the FDA
16 Dec 2019 Social FDA has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily use in moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers. https://t.co/L9lcHfosU1
11 Dec 2019 Social Biosimilar Tote-Board in Rheumatology: 4 Infliximab biosimilars - Inflectra, Renflexis, Ifixi, Avsola 5 Adalimumab biosimilars - Amjevita, Cyltezo, Hyrimoz, Hadlima, Abrilada 2 Etanercept biosimilars - Erelzi, Enticovo 2 Rituximab biosimilars - Truxima, Ruxience
11 Dec 2019 Social FDA has approved Amgen’s infliximab biosimilar, Avsola (infliximab-axxq),for use in Crohns, UC, RA, AS, PsA and psoriasis, based on a 566 pt trial in RA. This is the 4th infliximab biosimilar in the US, joining Inflectra, Renflexis, and Ixifi. https://t.co/nFhyMM1OnK
10 Dec 2019 News Variations in First Biologic Use in Rheumatoid Arthritis
10 Dec 2019 Social BEST JOURNAL TITLE OF THE WK - "The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis." https://t.co/9ncBmDbd6B
28 Nov 2019 Social RT @RheumNow: Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activ…
26 Nov 2019 Social The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA). https://t.co/cJFEk464Wr
26 Nov 2019 News BMS and Celgene Merge as Amgen Buys Otezla
21 Nov 2019 Social FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
20 Nov 2019 News ACR 2019 – Best of the Plenary Sessions
20 Nov 2019 ACR Video Subcutaneous Biosimilar: Dr. Jonathan Kay
18 Nov 2019 ACR Video Emapalumab Treatment in Macrophage Activation Syndrome: Dr. Fabrizio De Benedetti
18 Nov 2019 ACR Video Biosimilars: Dr. Arthur Kavanaugh